Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/CSNK1A1_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/CSNK1A1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/CSNK1A1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/CSNK1A1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/CSNK1A1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/CSNK1A1_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/CSNK1A1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/CSNK1A1_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/CSNK1A1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/CSNK1A1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/CSNK1A1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/CSNK1A1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00301115 | Liver | NAFLD | regulation of Wnt signaling pathway | 57/1882 | 328/18723 | 2.79e-05 | 7.46e-04 | 57 |
GO:00608285 | Liver | NAFLD | regulation of canonical Wnt signaling pathway | 44/1882 | 253/18723 | 2.14e-04 | 3.68e-03 | 44 |
GO:00600705 | Liver | NAFLD | canonical Wnt signaling pathway | 50/1882 | 303/18723 | 3.08e-04 | 4.83e-03 | 50 |
GO:19033647 | Liver | NAFLD | positive regulation of cellular protein catabolic process | 29/1882 | 155/18723 | 7.37e-04 | 9.36e-03 | 29 |
GO:00510987 | Liver | NAFLD | regulation of binding | 56/1882 | 363/18723 | 7.80e-04 | 9.77e-03 | 56 |
GO:20000607 | Liver | NAFLD | positive regulation of ubiquitin-dependent protein catabolic process | 22/1882 | 107/18723 | 8.56e-04 | 1.05e-02 | 22 |
GO:19030525 | Liver | NAFLD | positive regulation of proteolysis involved in cellular protein catabolic process | 25/1882 | 133/18723 | 1.54e-03 | 1.66e-02 | 25 |
GO:001049812 | Liver | Cirrhotic | proteasomal protein catabolic process | 216/4634 | 490/18723 | 2.52e-21 | 9.29e-19 | 216 |
GO:004217612 | Liver | Cirrhotic | regulation of protein catabolic process | 181/4634 | 391/18723 | 7.94e-21 | 2.77e-18 | 181 |
GO:000989612 | Liver | Cirrhotic | positive regulation of catabolic process | 215/4634 | 492/18723 | 1.13e-20 | 3.56e-18 | 215 |
GO:003133112 | Liver | Cirrhotic | positive regulation of cellular catabolic process | 190/4634 | 427/18723 | 1.94e-19 | 4.18e-17 | 190 |
GO:004316112 | Liver | Cirrhotic | proteasome-mediated ubiquitin-dependent protein catabolic process | 184/4634 | 412/18723 | 4.52e-19 | 8.85e-17 | 184 |
GO:190336212 | Liver | Cirrhotic | regulation of cellular protein catabolic process | 124/4634 | 255/18723 | 9.85e-17 | 1.26e-14 | 124 |
GO:004586212 | Liver | Cirrhotic | positive regulation of proteolysis | 163/4634 | 372/18723 | 4.18e-16 | 5.14e-14 | 163 |
GO:004573212 | Liver | Cirrhotic | positive regulation of protein catabolic process | 112/4634 | 231/18723 | 3.89e-15 | 4.21e-13 | 112 |
GO:190336412 | Liver | Cirrhotic | positive regulation of cellular protein catabolic process | 80/4634 | 155/18723 | 5.04e-13 | 3.86e-11 | 80 |
GO:190305012 | Liver | Cirrhotic | regulation of proteolysis involved in cellular protein catabolic process | 103/4634 | 221/18723 | 1.14e-12 | 8.61e-11 | 103 |
GO:200005812 | Liver | Cirrhotic | regulation of ubiquitin-dependent protein catabolic process | 81/4634 | 164/18723 | 7.22e-12 | 4.92e-10 | 81 |
GO:005109812 | Liver | Cirrhotic | regulation of binding | 148/4634 | 363/18723 | 9.14e-12 | 5.97e-10 | 148 |
GO:006113612 | Liver | Cirrhotic | regulation of proteasomal protein catabolic process | 84/4634 | 187/18723 | 1.28e-09 | 5.56e-08 | 84 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CSNK1A1 | SNV | Missense_Mutation | | c.178N>A | p.Glu60Lys | p.E60K | P48729 | protein_coding | deleterious_low_confidence(0.02) | probably_damaging(0.956) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
CSNK1A1 | insertion | Nonsense_Mutation | novel | c.33_34insCTTGTTAAACACGTCCCATAAATGTCCCTTAGTCGAG | p.Ile12LeufsTer7 | p.I12Lfs*7 | P48729 | protein_coding | | | TCGA-A8-A06U-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CSNK1A1 | insertion | In_Frame_Ins | novel | c.576_577insCCA | p.Tyr192_Arg193insPro | p.Y192_R193insP | P48729 | protein_coding | | | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
CSNK1A1 | deletion | Frame_Shift_Del | novel | c.166delN | p.Gln56SerfsTer33 | p.Q56Sfs*33 | P48729 | protein_coding | | | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
CSNK1A1 | SNV | Missense_Mutation | | c.62G>T | p.Arg21Leu | p.R21L | P48729 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.91) | TCGA-AA-3713-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | 5-fluorouracil | PR |
CSNK1A1 | SNV | Missense_Mutation | | c.929G>A | p.Arg310His | p.R310H | P48729 | protein_coding | deleterious_low_confidence(0) | benign(0.062) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
CSNK1A1 | SNV | Missense_Mutation | rs865943998 | c.854C>T | p.Ala285Val | p.A285V | P48729 | protein_coding | tolerated_low_confidence(0.13) | benign(0.261) | TCGA-AA-A022-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CSNK1A1 | SNV | Missense_Mutation | novel | c.812N>T | p.Thr271Met | p.T271M | P48729 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.493) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CSNK1A1 | SNV | Missense_Mutation | | c.292N>A | p.Glu98Lys | p.E98K | P48729 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.975) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CSNK1A1 | SNV | Missense_Mutation | novel | c.874N>T | p.Arg292Cys | p.R292C | P48729 | protein_coding | deleterious_low_confidence(0) | benign(0.062) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1452 | CSNK1A1 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | SP-600125 | SP-600125 | |
1452 | CSNK1A1 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | 178102608 | IC261 | |
1452 | CSNK1A1 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | AZD-1775 | ADAVOSERTIB | |
1452 | CSNK1A1 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | DNDI1417467 | CHEMBL1997335 | |
1452 | CSNK1A1 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | SB-220025 | SB-220025 | |
1452 | CSNK1A1 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | 178102563 | | |
1452 | CSNK1A1 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | 681640 | CHEMBL379975 | |
1452 | CSNK1A1 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | AG-1879 | CHEMBL406845 | |
1452 | CSNK1A1 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | PHA-767491 | CHEMBL225519 | |
1452 | CSNK1A1 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | TAK-715 | TAK-715 | |